Table 4.
Projected Cholesterol-Lowering Medications Utilization
| Patients receiving cholesterol-lowering medications | Patients in a commercial plan, N (%) (N = 4,402,866) | Patients in a Medicaid plan, N (%) (N = 2,173,914) | Patients in a Medicare plan, N (%) (N = 7,537,720) | Total population, N (%) (N = 14,114,500) | |
|---|---|---|---|---|---|
| Statin users, by dosing intensitya | Low-intensity statin | 27,252 (4.4) | 9342 (7.3) | 248,729 (6.0) | 285,323 (5.8) |
| Moderate-intensity statin | 392,928 (64.2) | 90,642 (70.8) | 2,566,826 (61.8) | 3,050,396 (62.3) | |
| High-intensity statin | 192,302 (31.4) | 28,021 (21.9) | 1,336,627 (32.2) | 1,556,950 (31.8) | |
| Total | 612,482 (13.91) | 128,005 (5.89) | 4,152,182 (55.09) | 4,892,668 (34.66) | |
| Statin and nonstatin cholesterol-lowering medication usersb | Total | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Nonstatin cholesterol-lowering medication users | Bile acid–binding resins | 5667 (22.4) | 1000 (19.1) | 48,163 (33.4) | 54,831 (31.4) |
| Cholesterol absorption inhibitors | 4801 (19.0) | 378 (7.2) | 41,549 (28.8) | 46,728 (26.8) | |
| Fibrates | 13,270 (52.5) | 4204 (80.1) | 77,550 (53.8) | 95,024 (54.4) | |
| Niacin | 3901 (15.4) | 790 (15.1) | 21,231 (14.7) | 25,922 (14.8) | |
| Omega-3 fatty acids | 7018 (27.8) | 535 (10.2) | 16,180 (11.2) | 23,733 (13.6) | |
| Total | 25,257 (0.57) | 5247 (0.24) | 144,137 (1.91) | 174,641 (1.24) | |
| All cholesterol-lowering medication usersc | Total | 637,739 (14.48) | 133,252 (6.13) | 4,296,319 (57.00) | 5,067,309 (35.90) |
| Patients aged 40–75 years not receiving cholesterol-lowering medications | |||||
| With diabetes claims | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| With hypertension claims, but no diabetes medication claim | 92,297 (6.51) | 16,516 (6.42) | 304,613 (17.18) | 413,426 (11.99) | |
| Overall total | 1,418,731 (32.22) | 257,067 (11.83) | 1,772,803 (23.52) | 3,448,601 (24.43) | |
a
See Table 1 for statin dosing intensity definitions.
b
These patients are receiving a statin and a nonstatin cholesterol-lowering medication, and these counts are not mutually exclusive of the patients counted under the statin and the nonstatin cholesterol-lowering medication user groups.
c
Unique members who are receiving any cholesterol-lowering medications.